

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

INSIDE INFORMATION

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.

Reference is made to the announcement of the Company dated 1 December 2016 (“**1 December Announcement**”) regarding the Company’s efforts in gaining control of the Company’s two indirectly wholly owned subsidiaries in the People’s Republic of China (“**PRC**”).

In this announcement, unless otherwise specified, the same abbreviations and descriptions used in the 1 December Announcement are adopted.

There are two separate civil complaints in the PRC made by the two subsidiaries SHMY Biochips and Shanghai HealthDigit against their current respective legal representatives (法定代表人) Yao and Iu.

The civil complaint in relation to SHMY Biochips had been heard by the Shanghai FengXian People’s court and judgment was handed down on 28 September 2017.

It is unfortunate that the judgment was against the Company on the basis that we had failed to prove that the original company seal and relevant licences of SHMY Biochips were in Yao’s possession, albeit Yao is its legal representative and by definition the custodian of the instruments. On the advice of the PRC lawyer, the Company will appeal against the judgment within the prescribed time limit.

** For identification purpose only*

As regards the matter concerning Shanghai HealthDigit, which legal representative is Iu, the court was informed that Iu was incapacitated to be a defendant because he had suffered serious stroke. The court had then adjourned the hearing to 20 October 2017.

The Company will inform the shareholders of further development of the matter.

Trading in shares of the Company will remain suspended pending satisfaction of the resumption conditions imposed by the Stock Exchange.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 10 October 2017

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Mr. Cheung Chi Ming and Ms. Fan Stephanie Winnie as independent non-executive Directors.